Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CardioGenesis tries again

This article was originally published in The Gray Sheet

Executive Summary

March meeting will provide another opportunity for firm to present case for PMA approval of PMR percutaneous myocardial revascularization system. FDA deemed the supplemental application "not approvable" in December 2002 (1"The Gray Sheet" March 3, 2003, p. 3). If a "favorable outcome" cannot be reached, CardioGenesis could opt to go before FDA's Medical Devices Dispute Resolution Panel...

You may also be interested in...

CardioGenesis’ PMR On Deck For FDA Dispute Resolution Panel Review

CardioGenesis is retaining Covington & Burling to help prepare for its upcoming dispute resolution panel. The regulatory law firm consulted Lifecore Biomedical in the only other MDDRP review

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 

NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks

NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts